ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1548

Treatment Effect of Ustekinumab on Fatigue in Patients with Psoriatic Arthritis: Results from a Phase 3 Clinical Trial

Christopher T. Ritchlin1, Proton Rahman2, Lluís Puig Sanz3, Alice B. Gottlieb4, Arthur Kavanaugh5, Iain B. McInnes6, Shu Li7, Yuhua Wang7, Rita Ganguly8, Alan M. Mendelsohn9 and Chenglong Han8, 1Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 3Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Tufts Medical Center, Boston, MA, 5University of California San Diego, La Jolla, CA, 6Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 7Janssen Research & Development, LLC., Spring House, PA, 8Janssen Global Services, LLC., Malvern, PA, 9Immunology, Janssen Research & Development, LLC., Spring House, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Fatigue, psoriatic arthritis and quality of life

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II

Session Type: Abstract Submissions (ACR)

Background/Purpose: To assess the treatment effect of ustekinumab on fatigue using data from PSUMMIT 2.

Methods: Adult patients with active psoriatic arthritis (PsA) despite DMARD (N=132) and/or previous treatment with biologics (N=180) were randomized to receive ustekinumab 45mg, 90mg, or placebo (PBO) at wks 0, 4, and q12wks thereafter through week 40.  PBO-treated patients crossed over to receive ustekinumab 45mg at weeks 24, 28 and q12wks through week 40. Fatigue was measured using the Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT-Fatigue, 0-52) and the vitality scales of SF-36 health survey questionnaire (SF-36 VT, 0-100). High scores indicate low severity in fatigue. Clinically meaningful improvement was defined as ≥4 point increase in FACIT-Fatigue or ≥3 point increase in SF-36 VT score from baseline. Disease activity was measured by disease activity score using 28 joints (DAS28), and physical function was measured using Health Assessment Questionnaire (HAQ).

Results:

At baseline, patients had a mean FACIT-Fatigue score of 25.8 and had a mean SF-36 VT score of 36.9, which was significantly below the values of the U.S. normal population (50), indicating severe fatigue.  Both FACIT-Fatigue and SF-36 VT scores were significantly correlated with DAS28 (r=0.42, 0.38, respectively) and HAQ (r=0.62, 0.51, respectively) at baseline, and the improvements in FACIT-Fatigue and SF-36 VT scores were significantly correlated with improvement in DAS28 (r=0.45, 0.43, respectively) and improvement in HAQ scores (r=0.43, 0.41, respectively) at week 24. At week 24, patients who received ustekinumab achieved statistically significantly greater improvement in FACIT-Fatigue score (4.35 vs. 0.86, p=0.002) and in SF-36 VT score (3.87 vs. 0.67, p=0.004) compared with PBO.  Compared to PBO, a greater proportion of ustekinumab-treated patients achieved a clinically meaningful improvement in FACIT-Fatigue (49% vs. 25.5%) or SF-36 VT (45% vs. 29.9%) (all p<0.01). No significant differences were observed between the ustekinumab 45 and 90mg groups. The treatment effect on fatigue was consistent across biologically-experienced and DMARD-experienced patients, and maintained through week 52. Patients who were randomized to PBO and switched to active treatment at week 24 achieved comparable improvement at week 52. 

Conclusion: Ustekinumab therapy significantly reduces the symptom of fatigue in patients with active PsA. Clinically meaningful improvement in fatigue was observed within 3 doses of ustekinumab therapy.


Disclosure:

C. T. Ritchlin,

Amgen, Janssen, and UCB ,

2,

Abbott, Amgen, Janssen, Regeneron, Roche, and UCB,

5;

P. Rahman,

Abbott, Amgen, Janssen, Merck/Schering-Plough, and Wyeth,

2;

L. Puig Sanz,

Abbott, Amgen, Celgene, Janssen Research & Development, LLC., Merck/Schering-Plough, and Pfizer,

2;

A. B. Gottlieb,

Amgen, Astellas, Akros, Celgene, BMS, Beiesrdorf, AbbVie,Janssen, TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor, Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, GSK, Xenoport, Catabasis, Sanofi Ave,

5,

Janssen, Amgen, AbbVie, Novartis, Celgene, Pfizer, Lilly, Coronado, Levia, Merck,

2;

A. Kavanaugh,

AbbVie,

2,

Amgen,

2,

Roche Pharmaceuticals,

2,

Pfizer Inc,

2,

Janssen Pharmaceutica Product, L.P.,

2,

UCB,

2,

BMS,

2,

Astellas,

2;

I. B. McInnes,

Pfizer Inc,

2,

UCB,

2,

Pfizer Inc,

5,

Janssen Pharmaceutica Product, L.P.,

5,

UCB,

5,

BMS,

5,

Abbvie,

5,

Astra Zeneca,

5;

S. Li,

Janssen Research & Development, LLC.,

3,

Johnson & Johnson,

1;

Y. Wang,

Janssen Research & Development, LLC.,

3;

R. Ganguly,

Janssen Global Services, LLC.,

3;

A. M. Mendelsohn,

Janssen Research & Development, LLC.,

3;

C. Han,

Janssen Global Services, LLC.,

3.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-effect-of-ustekinumab-on-fatigue-in-patients-with-psoriatic-arthritis-results-from-a-phase-3-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.